Stabilized YEVHHQ Peptide Derivatives for Neuroprotection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease are limited in effectively addressing neurodegeneration and have no significant impact on the progression of the disease, with existing therapies only providing transient relief for a portion of the population.
Innovation Solution
A core six-amino acid sequence, Tyrosine-Glutamate-Valine-Histidine-Histidine-Glutamine (YEVHHQ), is stabilized and transformed into derivatives or peptidomimetics to serve as a therapeutic agent, offering neuroprotective activity against beta-amyloid toxicity, thereby addressing synaptic dysfunction and neurodegeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for Alzheimer's disease are used, then transient relief of early symptoms is achieved, but no significant impact on disease progression or neurodegeneration occurs
Solution Approach 1:
The patent extracts the core neurotoxic hexapeptide sequence (YEVHHQ) from the full-length beta-amyloid protein to create a stabilized derivative that specifically targets and neutralizes toxic Aβ oligomers, providing sustained neuroprotection rather than transient symptom relief
Solution Approach 2:
The stabilized YEVHHQ derivative is designed to prevent neurodegeneration by binding to and neutralizing toxic Aβ oligomers before they can cause irreversible damage to synapses and neurons, thereby addressing disease progression proactively rather than merely providing transient symptomatic relief
2Adaptability or versatility
If current treatments are administered, then a portion of the population experiences transient symptom relief, but no significant impact on neurodegeneration occurs
Solution Approach 1:
The patent converts the harmful neurotoxic YEVHHQ sequence of beta-amyloid into a beneficial therapeutic agent by creating a stabilized derivative that binds to and neutralizes toxic Aβ oligomers, transforming the disease-causing element into a disease-fighting treatment
3Object-affected harmful factors
If beta-amyloid accumulates in the brain, then synaptic impairment occurs, but no effective cure or disease-modifying treatment exists
Solution Approach 1:
The stabilized YEVHHQ derivative acts as an intermediary that binds to toxic Aβ oligomers, preventing them from interacting with and damaging synapses and neurons, thereby providing a mechanism to counteract beta-amyloid toxicity
Data Source
AI summary
Peptide analogues of β-amyloid and methods of using said analogues for neuroprotection are described herein. The β-amyloid peptide analogues have a sequence that is at least 50% identical to an N-terminal β-amyloid core fragment. A pharmaceutical composition of the β-amyloid peptide analogues in a pharmaceutically acceptable carrier can be administered to a subject for neuromodulation. The β-amyloid peptide analogues, while lacking neurotoxicity, effectively provides for protective activity against β-amyloid toxicity.